Eton Pharmaceuticals, Inc. - Common Stock (ETON)

Eton's cure for an expensive valuation: a 99% sales growth rate.

Eton Pharmaceuticals (NASDAQ:ETON) reported second-quarter revenue nearly doubled from a year earlier, driven by the relaunch of HEMANGEOL and growth across its pediatric endocrinology and rare-disease portfolio. The company raised its full-year revenue and profitability outlook while outlining plan

Eton Pharmaceuticals (NASDAQ:ETON) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. Benzinga APIs provide real-time

Eton (ETON) Q1 2026 Earnings Call Transcript

Eton Pharmaceuticals (NASDAQ:ETON) raised its 2026 revenue outlook after reporting record first-quarter product sales and highlighting early progress from two recent product launches, DESMODA and HEMANGEOL. Chief Executive Officer Sean Brynjelsen said the company now expects full-year revenue to ex

Eton Pharma (ETON) Earnings Call Transcript

Immunome develops antibody therapeutics for cancer and infectious diseases, reporting a market cap above $2 billion in the latest filing.

Liquidia develops inhaled and injectable therapies for pulmonary arterial hypertension, targeting unmet needs in the U.S. biopharma market.

Eton Pharma (ETON) Q3 2025 Earnings Transcript

Eton Pharmaceuticals Q3 2025 results: A mixed quarter with a 7.6% revenue beat but a miss on earnings per share.

Eton Pharma's Khindivi has won FDA approval as a pediatric adrenal insufficiency treatment. It is projected to surge in sales and launch in the U.S. in June 2025.

A fundamental and technical analysis of (NASDAQ:ETON): Is ETON PHARMACEUTICALS INC (NASDAQ:ETON) suited for high growth investing?